SB 211475, a metabolite of carvedilol, reduces infarct size after myocardial ischemic and reperfusion injury in rabbits
- 22 September 1998
- journal article
- research article
- Published by Elsevier in European Journal of Pharmacology
- Vol. 356 (2-3) , 193-198
- https://doi.org/10.1016/s0014-2999(98)00494-4
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Carvedilol improves function and reduces infarct size in the feline myocardium by protecting against lethal reperfusion injuryEuropean Journal of Pharmacology, 1996
- Carvedilol Protects Against Lethal Reperfusion Injury Through Antiadrenergic MechanismsJournal of Cardiovascular Pharmacology, 1996
- Carvedilol, a novel multiple action antihypertensive agent with antioxidant activity and the potential for myocardial and vascular protectionEuropean Heart Journal, 1995
- Cardioprotective effects of carvedilol, a novel adrenoceptor antagonist with vasodilating properties, in anaesthetised minipigs: comparison with propranololCardiovascular Research, 1992
- Myocardial Protection with CarvedilolJournal of Cardiovascular Pharmacology, 1992
- Neutrophil accumulation in ischemic canine myocardium. Insights into time course, distribution, and mechanism of localization during early reperfusion.Circulation, 1991
- Oxygen-derived free radicals and myocardial reperfusion injury: An overviewCardiovascular Drugs and Therapy, 1991
- Mechanism of myocardial "stunning".Circulation, 1990
- Myocardial blood flow conditions at re-perfusion following acute ischaemiaScandinavian Journal of Clinical and Laboratory Investigation, 1985
- A critical look at currently used indirect indices of myocardial oxygen consumptionBasic Research in Cardiology, 1981